HBV-TAG 2021 Conference (Sponsorship)

Published on 18/05/2021

11-12 June 2021
Virtual Conference

ENYO Pharma has sponsored the 2021 Inaugural Virtual Hepatitis B – Therapeutic Agents Conference.
www.hbv-tag.org

“The primary objective of the Virtual HBV-TAG Conference is to meet the educational needs of research and development stakeholders and healthcare professionals who seek to improve the lives of patients with HBV. The aim of the HBV-TAG conference is to bring together key opinion leaders from the teams of clinicians that care for patients with HBV (hepatologists and gastroenterologists) and pharmaceutical industry representatives to discuss optimized trial design, patient populations, therapeutic endpoints, as well as the potential benefits these agents can have for patients with HBV. This conference will deliver a focused scientific educational update that highlights the most clinically relevant advances in HBV to guide future directions in diagnostic procedures and the development of therapeutic agents for HBV. ”

The virtual exhibit booth was a great opportunity to present the preliminary results of our lead compound, Vonafexor (EYP001, FXR agonist) in Phase 2a study treating naive patients with chronic Hepatitis B :

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US